Clinical Trial Update: A Clinical Study to Enable Process Validation of Commercial Grade OTL-101 [Phase 2, Phase 3]

View source ↗

Summary

A clinical study aimed at enabling process validation for OTL-101 has been withdrawn after Phase 2/3 was in progress.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency Due to Ada Deficiency

Drugs mentioned

• OTL-101

Snippet

Sponsor: University of California, Los Angeles | Conditions: Severe Combined Immunodeficiency Due to ADA Deficiency | Phase 2, Phase 3 | Status: WITHDRAWN